Literature DB >> 30224518

Deficiency of the Endocytic Protein Hip1 Leads to Decreased Gdpd3 Expression, Low Phosphocholine, and Kypholordosis.

Ranjula Wijayatunge1, Sam R Holmstrom1, Samantha B Foley1, Victoria E Mgbemena1, Varsha Bhargava1, Gerardo Lopez Perez1, Kelly McCrum1, Theodora S Ross2.   

Abstract

Deficiency of huntingtin-interacting protein 1 (Hip1) results in degenerative phenotypes. Here we generated a Hip1 deficiency allele where a floxed transcriptional stop cassette and a human HIP1 cDNA were knocked into intron 1 of the mouse Hip1 locus. CMV-Cre-mediated germ line excision of the stop cassette resulted in expression of HIP1 and rescue of the Hip1 knockout phenotype. Mx1-Cre-mediated excision led to HIP1 expression in spleen, kidney and liver, and also rescued the phenotype. In contrast, hGFAP-Cre-mediated, brain-specific HIP1 expression did not rescue the phenotype. Metabolomics and microarrays of several Hip1 knockout tissues identified low phosphocholine (PC) levels and low glycerophosphodiester phosphodiesterase domain containing 3 (Gdpd3) gene expression. Since Gdpd3 has lysophospholipase D activity that results in the formation of choline, a precursor of PC, Gdpd3 downregulation could lead to the low PC levels. To test whether Gdpd3 contributes to the Hip1 deficiency phenotype, we generated Gdpd3 knockout mice. Double knockout of Gdpd3 and Hip1 worsened the Hip1 phenotype. This suggests that Gdpd3 compensates for Hip1 loss. More-detailed knowledge of how Hip1 deficiency leads to low PC will improve our understanding of HIP1 in choline metabolism in normal and disease states.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Cre recombinase; GDE7; GDPD3; HIP1; endocytosis; kypholordosis; phosphocholine

Mesh:

Substances:

Year:  2018        PMID: 30224518      PMCID: PMC6234285          DOI: 10.1128/MCB.00385-18

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  57 in total

1.  Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

Authors:  Sai-Hong Ignatius Ou; Samuel J Klempner; Joel R Greenbowe; Michele Azada; Alexa B Schrock; Siraj M Ali; Jeffrey S Ross; Philip J Stephens; Vincent A Miller
Journal:  J Thorac Oncol       Date:  2014-12       Impact factor: 15.609

2.  Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.

Authors:  Maria D Cao; Mailin Döpkens; Balaji Krishnamachary; Farhad Vesuna; Mayur M Gadiya; Per E Lønning; Zaver M Bhujwalla; Ingrid S Gribbestad; Kristine Glunde
Journal:  NMR Biomed       Date:  2012-01-26       Impact factor: 4.044

Review 3.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

4.  HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain.

Authors:  M A Kalchman; H B Koide; K McCutcheon; R K Graham; K Nichol; K Nishiyama; P Kazemi-Esfarjani; F C Lynn; C Wellington; M Metzler; Y P Goldberg; I Kanazawa; R D Gietz; M R Hayden
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

Review 5.  Choline metabolism in malignant transformation.

Authors:  Kristine Glunde; Zaver M Bhujwalla; Sabrina M Ronen
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

6.  Use of a cryptic splice site for the expression of huntingtin interacting protein 1 in select normal and neoplastic tissues.

Authors:  Chiron W Graves; Steven T Philips; Sarah V Bradley; Katherine I Oravecz-Wilson; Lina Li; Alice Gauvin; Theodora S Ross
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

7.  HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains.

Authors:  Teresa S Hyun; Dinesh S Rao; Djenann Saint-Dic; L Evan Michael; Priti D Kumar; Sarah V Bradley; Ikuko F Mizukami; Katherine I Oravecz-Wilson; Theodora S Ross
Journal:  J Biol Chem       Date:  2004-01-19       Impact factor: 5.157

8.  Role of the ENTH domain in phosphatidylinositol-4,5-bisphosphate binding and endocytosis.

Authors:  T Itoh; S Koshiba; T Kigawa; A Kikuchi; S Yokoyama; T Takenawa
Journal:  Science       Date:  2001-02-09       Impact factor: 47.728

Review 9.  The emerging physiological roles of the glycerophosphodiesterase family.

Authors:  Daniela Corda; Maria G Mosca; Noriyasu Ohshima; Laura Grauso; Noriyuki Yanaka; Stefania Mariggiò
Journal:  FEBS J       Date:  2014-01-15       Impact factor: 5.542

10.  Enhanced identification and biological validation of differential gene expression via Illumina whole-genome expression arrays through the use of the model-based background correction methodology.

Authors:  Liang-Hao Ding; Yang Xie; Seongmi Park; Guanghua Xiao; Michael D Story
Journal:  Nucleic Acids Res       Date:  2008-05-01       Impact factor: 16.971

View more
  3 in total

1.  Human GDPD3 overexpression promotes liver steatosis by increasing lysophosphatidic acid production and fatty acid uptake.

Authors:  Chia-Chi C Key; Andrew C Bishop; Xianfeng Wang; Qingxia Zhao; Guan-Yuan Chen; Matthew A Quinn; Xuewei Zhu; Qibin Zhang; John S Parks
Journal:  J Lipid Res       Date:  2020-05-19       Impact factor: 5.922

2.  The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cells.

Authors:  Kazuhito Naka; Ryosuke Ochiai; Eriko Matsubara; Chie Kondo; Kyung-Min Yang; Takayuki Hoshii; Masatake Araki; Kimi Araki; Yusuke Sotomaru; Ko Sasaki; Kinuko Mitani; Dong-Wook Kim; Akira Ooshima; Seong-Jin Kim
Journal:  Nat Commun       Date:  2020-09-17       Impact factor: 14.919

Review 3.  Endocytic Adaptor Proteins in Health and Disease: Lessons from Model Organisms and Human Mutations.

Authors:  Domenico Azarnia Tehran; Tania López-Hernández; Tanja Maritzen
Journal:  Cells       Date:  2019-10-29       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.